g , Representative images showing Left: oNLS-oScarlet expression in the CeA, Middle: merged image, Right: magnified view of the merged image
Important: Retatrutide remains an investigational agent and is not approved for human therapy
Early-stage research continues, but clinical evidence does not yet support patches as a substitute for established injection or oral therapies
Semaglutide: GLP-1 receptor agonist (anti-diabetic agent), enhances glycemic control through insulin secretion, slowing gastric emptying, and reducing postprandial glucagon secretion
By discussing results openly and focusing on rationalising therapy rather than attributing blame, and applying motivational interviewing and life style medicine principles, we saw a genuine shift in patient engagement people became more receptive, motivated, and empowered to take ownership of their health